Abstract When drafting the Principles of European Tort Law (PETL), members Group on decided to omit wrongfulness as a specific requirement for civil liability, considering it concept underlying notions interference with legally protected interests and standard conduct. This paper tends demonstrate that this terminological conceptual choice is still valid eighteen years after publication PETL. O...

Abstract Artificial intelligence (AI) is almost ubiquitous, featuring innumerable facets of daily life. For all its advantages, however, it carries risks harm. In this article, we discuss how the law tort should deal with these risks. We take account need for any proposed scheme liability to protect existing values without acting as a barrier innovation. To end, propose strict regime in respect...

As a rule, mentally ill patients are held to be responsible for their acts just like everyone else. Notwithstanding, the law in Israel contains special rules which distinguish individuals with mental illness from other people. The instructions laid out in article 34h of the Israeli Penal Law empower the court to release a defendant from criminal responsibility. To do this the following criteria...

State apology laws offer a separate avenue from traditional damages-centric tort reforms to address medical malpractice liability. These laws facilitate apologies from physicians by excluding statements of apology from malpractice trials. Prior research suggests that apologies may assuage the anger of patients, decrease the number of claims filed, and lower settlement amounts. Using a unique da...

Federal regulations governing human subjects research do not address key questions raised by incidental neuroimaging findings, including the scope of a researcher's disclosure with respect to the possibility of incidental findings and the question whether a researcher has an affirmative legal cuty to seek, detect, and report incidental findings. The scope of researcher duties may, however, be m...

Multiple stakeholders in the U.S. health care system are also paying closer attention than ever to the safety and efficacy of treatments and monitoring how pharmaceutical companies report the results of their clinical trials. A consequence of this scrutiny is the number of mass tort and product liability cases in which pharmaceutical companies’ analyses, interpretations and reporting of biologi...